Related Experiment Video
Updated: May 14, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Design, synthesis, and functional evaluation of leukocyte function associated antigen-1 antagonists in early and late
Eider San Sebastián1, Tahl Zimmerman, Aizpea Zubia
1Ikerchem Ltd., 20009 San Sebastián, Spain.
Abstract:
The integrin leukocyte function associated antigen 1 (LFA-1) binds the intercellular adhesion molecule 1 (ICAM-1) by its α(L)-chain inserted domain (I-domain). This interaction plays a key role in cancer and other diseases. We report the structure-based design, small-scale synthesis, and biological activity evaluation of a novel family of LFA-1 antagonists. The design led to the synthesis of a family of highly substituted homochiral pyrrolidines with antiproliferative and antimetastatic activity in a murine model of colon carcinoma, as well as potent antiadhesive properties in several cancer cell lines in the low micromolar range. NMR analysis of their binding to the isolated I-domain shows that they bind to the I-domain allosteric site (IDAS), the binding site of other allosteric LFA-1 inhibitors. These results provide evidence of the potential therapeutic value of a new set of LFA-1 inhibitors, whose further development is facilitated by a synthetic strategy that is versatile and fully stereocontrolled.
Insights
Researchers designed novel pyrrolidine-based antagonists targeting leukocyte function-associated antigen 1 (LFA-1). These compounds show promise in inhibiting cancer cell proliferation, metastasis, and adhesion, offering potential new therapeutic strategies.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Oncology
Background:
- Leukocyte function-associated antigen 1 (LFA-1) interacts with intercellular adhesion molecule 1 (ICAM-1), a process crucial in cancer progression.
- The LFA-1/ICAM-1 pathway is a significant target for therapeutic intervention in various diseases, including cancer.
Purpose of the Study:
- To report the structure-based design and synthesis of novel LFA-1 antagonists.
- To evaluate the biological activity, including antiproliferative, antimetastatic, and antiadhesive properties, of these new compounds.
Main Methods:
- Structure-based design of LFA-1 antagonists.
- Small-scale synthesis of highly substituted homochiral pyrrolidines.
- In vitro evaluation of antiadhesive properties in cancer cell lines.
- In vivo assessment of antiproliferative and antimetastatic activity in a murine colon carcinoma model.
- Nuclear Magnetic Resonance (NMR) analysis to determine binding site.
Main Results:
- A novel family of homochiral pyrrolidine LFA-1 antagonists was synthesized.
- Compounds demonstrated potent antiadhesive properties in cancer cell lines (low micromolar range).
- Demonstrated antiproliferative and antimetastatic activity in a murine colon carcinoma model.
- NMR studies confirmed binding to the I-domain allosteric site (IDAS).
Conclusions:
- The synthesized pyrrolidines represent a promising new class of LFA-1 inhibitors.
- These compounds exhibit significant therapeutic potential for cancer treatment.
- The versatile and stereocontrolled synthetic strategy facilitates further drug development.
